Patents Assigned to Takeda Pharmaceutical Company Limited
  • Heterocyclic compounds
    Patent number: 11447488
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 20, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomoaki Hasui, Shinji Nakamura, Satoshi Mikami, Tohru Yamashita
  • ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
    Publication number: 20220291232
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • HETEROCYCLIC COMPOUND
    Publication number: 20220289679
    Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuta TANAKA, Yuta TANAKA, Keiko KAKEGAWA, Takahito KASAHARA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Tomohiro OHASHI, Zenichi IKEDA, Florian PUENNER, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
  • Heterocyclic compound and use thereof
    Patent number: 11440883
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 13, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Formulation of an antibody and use thereof
    Patent number: 11433029
    Abstract: The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 6, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Markus Rast, Wolfgang Ise, Gerhard Becker, Peter Skufca, Henning Gieseler
  • Anti-CD38 antibodies
    Patent number: 11434304
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: September 6, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • HETEROCYCLIC COMPOUND
    Publication number: 20220274982
    Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 1, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuta TANAKA, Yuta TANAKA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Yasufumi WADA, Keiko KAKEGAWA, Takahito KASAHARA, Tomohiro OHASHI, Junsi WANG, Zenichi IKEDA, Florian PUENNER, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
  • INFUSION SYSTEM
    Publication number: 20220273871
    Abstract: An infusion system includes a pump unit and a motor unit. The pump unit may be configured to receive and/or retain at least one container of medicinal fluid, and may include a fluid distribution system at least partially engaged with a peristaltic pump head disposed in the pump unit. The motor unit may be removably received in the pump unit and coupled to the peristaltic pump head to drive fluid from the container to a fluid outlet that is couplable to an infusion set.
    Type: Application
    Filed: July 7, 2020
    Publication date: September 1, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Dhairya Kiritkumar Mehta, Ling Zheng
  • PURIFICATION OF FACTOR VIII SUBSPECIES
    Publication number: 20220275058
    Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 1, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
  • Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
    Patent number: 11426397
    Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 30, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason Green, Maria Hopkins, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Holger Monenschein, Sean Murphy, Thomas Nixey, Huikai Sun
  • ADENO-ASSOCIATED VIRUS PURIFICATION METHODS
    Publication number: 20220267796
    Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken at room temperature, and AAV is eluted from the affinity resin at a lower temperature. Various buffers are disclosed for use in the wash steps and elution.
    Type: Application
    Filed: June 26, 2020
    Publication date: August 25, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Christian FIEDLER, Marcus SCHEINDEL, Meinhard HASSLACHER, Jadranka KOEHN
  • Virus filtration of cell culture media
    Patent number: 11421202
    Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 23, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Wolfgang Mundt, Artur Mitterer, Manfred Reiter, Meinhard Hasslacher, Leopold Grillberger, Thomas Kreil
  • Anti-CD38 binding domains
    Patent number: 11414496
    Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 16, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Vinay Bhaskar, Erin Willert
  • TRANSFECTION METHOD
    Publication number: 20220249665
    Abstract: A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into cells (excluding immune cells) is provided by the present invention. Specifically, a system for delivering a target substance into a cell (excluding immune cells), including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid, a protein or a low-molecular-weight compound into a cell (excluding immune cells) by using the ultrafine bubble water, etc.; and the like are provided.
    Type: Application
    Filed: June 26, 2019
    Publication date: August 11, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Naoyuki MURATA, Shigeo YANAI
  • ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS FOR USE IN TREATING REFRACTORY COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE
    Publication number: 20220249574
    Abstract: Provided herein are expanded allogeneic adipose tissue-derived stromal stem cells for use in treating complex perianal fistulas in Crohn's Disease.
    Type: Application
    Filed: February 14, 2022
    Publication date: August 11, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Eduardo BRAVO, Maria PASCUAL
  • SCREENING METHOD AND TOXICITY EVALUATION METHOD
    Publication number: 20220252575
    Abstract: A method for screening for a therapeutic drug for a disease involving excessive activation of a complement, using a s cytotoxicity marker associated with the complement as an index, including (1a) a step of adding a complement to a cell produced from a stem cell to cause the cell to form a cytotoxicity marker associated with the complement, and (2a) a step of adding a therapeutic drug candidate, and selecting a substance that decreases the amount of the cytotoxicity marker is provided by the present invention.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 11, 2022
    Applicants: Public University Corporation Yokohama City University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori TAKEBE, Norikazu SAIKI, Yasunori NIO, Eri KAWAKAMI
  • TRANSFECTION METHOD
    Publication number: 20220251576
    Abstract: A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into immune cells such as T cell and the like is provided by the present invention. Thus, a system for delivering a target substance into an immune cell, including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid or a protein into an immune cell by using the ultrafine bubble water, etc. and ultrasound; and the like are provided.
    Type: Application
    Filed: June 25, 2020
    Publication date: August 11, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Naoyuki MURATA, Sayan CHUANOI, Shigeo YANAI
  • Constrained conditionally activated binding proteins
    Patent number: 11406710
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 9, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
    Patent number: 11407748
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Tomoaki Hasui, Tohru Yamashita, Shinji Morimoto, Hidekazu Tokuhara, Norio Oyabu, Masami Yamada, Atsuko Ochida, Kazuaki Takami, Xin Liu
  • Methods for purification of arysulfatase A
    Patent number: 11407984
    Abstract: The present invention provides, among other things, improved methods for purifying arylsulfatase A (ASA) protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant ASA protein can be purified from unprocessed biological materials, such as, ASA-containing cell culture medium, using a process involving as few as four chromatography columns and only one step of post-chromatographic ultrafiltration/diafiltration.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Dave Nichols, Igor Quinones-Garcia, Mei Huei Jang, Bee Lin Cheang